Evidence map›Paper›PMID 36263849›Full record

ArticleFEBS open bio2022

Haemophilus influenzae Protein D antibody suppression in a multi-component vaccine formulation.

Lea V Michel, Ravinder Kaur, Michael L Gleghorn, Melody Holmquist, Karin Pryharski, Janai Perdue, Seth P Jones, Niaya Jackson, Isabelle Pilo, Anna Kasper and 2 more

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Lea V MichelSchool of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.ORCID 0000-0001-6104-4646
Ravinder KaurCenter for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, NY, USA.
Michael L GleghornSchool of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
Melody HolmquistNational Technical Institute for the Deaf, Rochester Institute of Technology, NY, USA.
Karin PryharskiCenter for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, NY, USA.
Janai PerdueSchool of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
Seth P JonesSchool of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
Niaya JacksonSchool of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
Isabelle PiloSchool of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
Anna KasperSchool of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
Natalie LabbeSchool of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
Michael PichicheroCenter for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, NY, USA.
Rochester Institute of Technology · USRochester General Hospital · US

Funding

Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzaeR21AI153936 · NIAID · ROCHESTER GENERAL HOSPITAL (NY) · PI KAUR, RAVINDER · 2020 to 2021
$440k
NIAID NIH HHS R21 AI153936
6 · The paper itself

Abstract

Nontypeable Haemophilus influenzae (NTHi) has emerged as a dominant mucosal pathogen causing acute otitis media (AOM) in children, acute sinusitis in children and adults, and acute exacerbations of chronic bronchitis in adults. Consequently, there is an urgent need to develop a vaccine to protect against NTHi infection. A multi-component vaccine will be desirable to avoid emergence of strains expressing modified proteins allowing vaccine escape. Protein D (PD), outer membrane protein (OMP) 26, and Protein 6 (P6) are leading protein vaccine candidates against NTHi. In pre-clinical research using mouse models, we found that recombinantly expressed PD, OMP26, and P6 induce robust antibody responses after vaccination as individual vaccines, but when PD and OMP26 were combined into a single vaccine formulation, PD antibody levels were significantly lower. We postulated that PD and OMP26 physiochemically interacted to mask PD antigenic epitopes resulting in the observed effect on antibody response. However, column chromatography and mass spectrometry analysis did not support our hypothesis. We postulated that the effect might be in vivo through the mechanism of protein vaccine immunologic antigenic competition. We found when PD and OMP26 were injected into the same leg or separate legs of mice, so that antigens were immunologically processed at the same or different regional lymph nodes, respectively, antibody levels to PD were significantly lower with same leg vaccination. Different leg vaccination produced PD antibody levels quantitatively similar to vaccination with PD alone. We conclude that mixing PD and OMP26 into a single vaccine formulation requires further formulation studies.

Indexed as

Haemophilus VaccinesAnimalsAntibodies, BacterialBacterial Outer Membrane ProteinsHaemophilus influenzaeImmunoglobulin GMiceAntibodies, BacterialBacterial Outer Membrane ProteinsHaemophilus VaccinesImmunoglobulin Gacute otitis mediaantibody suppressionantigenic competitionHaemophilus influenzaeouter membrane protein 26Protein D

Identifiers

PMID36263849
PMCPMC9714371
OpenAlexW4306867736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.